DOP2022000137A - Compuesto de piridazinil-tiazolcarboxamida - Google Patents

Compuesto de piridazinil-tiazolcarboxamida

Info

Publication number
DOP2022000137A
DOP2022000137A DO2022000137A DO2022000137A DOP2022000137A DO P2022000137 A DOP2022000137 A DO P2022000137A DO 2022000137 A DO2022000137 A DO 2022000137A DO 2022000137 A DO2022000137 A DO 2022000137A DO P2022000137 A DOP2022000137 A DO P2022000137A
Authority
DO
Dominican Republic
Prior art keywords
treatment
cancer
compound
antibodies
pyridazinyl
Prior art date
Application number
DO2022000137A
Other languages
English (en)
Inventor
Watanabe Hideyuki
SEKI Yohei
Okuyama Keiichiro
Kurosawa Kazuo
Ikeda Osamu
Tomiyama Hiroshi
Iwai Yoshinori
Nakamura Akihiko
Miyasaka Kozo
Original Assignee
Astellas Pharma Inc
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of DOP2022000137A publication Critical patent/DOP2022000137A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Abstract

Se proporciona un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o el cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1. Los inventores de la presente han realizado estudios sobre un compuesto útil como principio activo de una composición farmacéutica para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1 y descubrieron que un compuesto de piridazinil- tiazolcarboxamida tiene efecto inhibitorio sobre DGK ¿ (DGKzeta), lo que da lugar a la consecución de la presente invención. El compuesto de piridazinil- tiazolcarboxamida de la presente invención tiene efecto inhibitorio sobre DGK ¿ y puede usarse como agente terapéutico para el tratamiento del cáncer relacionado con la activación de células inmunitarias o del cáncer que ofrece resistencia a un tratamiento con anticuerpos anti- PD- 1/anticuerpos anti- PD- L1.
DO2022000137A 2019-12-25 2022-06-24 Compuesto de piridazinil-tiazolcarboxamida DOP2022000137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019233673 2019-12-25
PCT/JP2020/048337 WO2021132422A1 (ja) 2019-12-25 2020-12-24 ピリダジニルチアアゾールカルボキシアミド化合物

Publications (1)

Publication Number Publication Date
DOP2022000137A true DOP2022000137A (es) 2022-11-30

Family

ID=76574296

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2022000137A DOP2022000137A (es) 2019-12-25 2022-06-24 Compuesto de piridazinil-tiazolcarboxamida

Country Status (21)

Country Link
US (1) US20220315603A1 (es)
EP (1) EP4083038A4 (es)
JP (1) JP6948659B1 (es)
KR (1) KR20220119702A (es)
CN (3) CN113365994A (es)
AR (1) AR120896A1 (es)
AU (1) AU2020413997A1 (es)
BR (1) BR112022012637A2 (es)
CA (1) CA3165889A1 (es)
CL (1) CL2022001752A1 (es)
CO (1) CO2022009124A2 (es)
CR (1) CR20220328A (es)
DO (1) DOP2022000137A (es)
EC (1) ECSP22057324A (es)
IL (1) IL294136A (es)
JO (1) JOP20220163A1 (es)
MX (1) MX2022007993A (es)
PE (1) PE20230163A1 (es)
TW (1) TW202136275A (es)
WO (1) WO2021132422A1 (es)
ZA (1) ZA202207543B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20230376A1 (es) 2019-12-24 2023-03-06 Carna Biosciences Inc Compuestos moduladores de la diacilglicerol quinasa
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CN115697979A (zh) 2020-04-24 2023-02-03 拜耳公司 作为用于免疫激活的dgkzeta抑制剂的取代的氨基噻唑类
CA3203285A1 (en) 2020-11-30 2022-06-02 Astellas Pharma Inc. Heteroaryl carboxamide compound
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381401B2 (en) 2004-01-08 2008-06-03 The University Of Chicago T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase
TWI422376B (zh) * 2005-01-25 2014-01-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之化合物
US8455658B2 (en) * 2006-01-25 2013-06-04 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
EP2009005A4 (en) * 2006-04-19 2010-06-02 Astellas Pharma Inc AZOLECARBOXAMIDE DERIVATIVE
CN101578275A (zh) * 2006-10-31 2009-11-11 先灵公司 苯胺基哌嗪衍生物及其使用方法
LT3814348T (lt) * 2018-06-27 2023-10-10 Bristol-Myers Squibb Company Pakeistieji naftiridinono junginiai, naudotini kaip t ląstelių aktyvatoriai
AR120896A1 (es) * 2019-12-25 2022-03-30 Astellas Pharma Inc COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz
CA3203285A1 (en) * 2020-11-30 2022-06-02 Astellas Pharma Inc. Heteroaryl carboxamide compound

Also Published As

Publication number Publication date
CR20220328A (es) 2022-08-30
CO2022009124A2 (es) 2022-07-19
BR112022012637A2 (pt) 2022-09-06
CN115590854A (zh) 2023-01-13
KR20220119702A (ko) 2022-08-30
US20220315603A1 (en) 2022-10-06
AU2020413997A1 (en) 2022-06-09
ECSP22057324A (es) 2022-08-31
CL2022001752A1 (es) 2023-03-10
JPWO2021132422A1 (ja) 2021-12-23
EP4083038A4 (en) 2023-12-20
ZA202207543B (en) 2023-12-20
AR120896A1 (es) 2022-03-30
JP6948659B1 (ja) 2021-10-13
CN115626919A (zh) 2023-01-20
EP4083038A1 (en) 2022-11-02
PE20230163A1 (es) 2023-02-01
JOP20220163A1 (ar) 2023-01-30
TW202136275A (zh) 2021-10-01
CA3165889A1 (en) 2021-07-01
WO2021132422A1 (ja) 2021-07-01
IL294136A (en) 2022-08-01
CN113365994A (zh) 2021-09-07
MX2022007993A (es) 2022-07-21

Similar Documents

Publication Publication Date Title
DOP2022000137A (es) Compuesto de piridazinil-tiazolcarboxamida
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2019000510A1 (es) Adenovirus armado con un activador de células t biespecífico (bite).
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CR20150523A (es) Uso de 2,3-dihidroimidazo [1,2-c]quinazolinas sustituidas
CL2016000837A1 (es) “formas isoméricas especificas del 7-hidroxi-6,8-dioxo-n-(2,4,6-triflúorobencil)-1,2,3,4,6,8,12,12a-octahidro-1,4-metanodipirido[1,2-a:1’,2’-d]pirazina-9-carboxamida; composición farmacéutica que los comprende; y su uso en el tratamiento de una infección por vih”.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
CL2019003589A1 (es) Derivado de n2,n4-difenilpirimidin-2,4-diamina, método para la preparación del mismo, y una composición farmacéutica que contiene el mismo como ingrediente activo para la prevención o tratamiento de cáncer.
AR108021A1 (es) Conjugados de anticuerpo-principio activo (adcs) de inhibidores de ksp con anticuerpos anti-b7h3
DOP2023000107A (es) Compuesto de heteroarilcarboxamida
CO2019007823A2 (es) Anticuerpo anti-cd3 y moléculas que comprenden el anticuerpo
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
BR112015028244A2 (pt) Imunoconjugado que se liga ao folr1 e seu uso
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
BR112019004496A2 (pt) estabilizantes de mastócitos para tratamento de hipercitocinemia e infecção viral
BR112018002530A2 (pt) combinações e usos e tratamentos destas
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
ECSP20023626A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
CO2020007601A2 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.